[Antimicrobial peptides: A new alternative for the treatment of aspergillosis].
C Rochard, J Bigot, V Balloy, C Hennequin, J Guitard
Author Information
C Rochard: Sorbonne université, Inserm, centre de recherche Saint-Antoine, CRSA, Paris, France.
J Bigot: Service de parasitologie-mycologie, hôpital Saint-Antoine, AP-HP, Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, 75012 Paris, France.
V Balloy: Sorbonne université, Inserm, centre de recherche Saint-Antoine, CRSA, Paris, France.
C Hennequin: Service de parasitologie-mycologie, hôpital Saint-Antoine, AP-HP, Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, 75012 Paris, France.
J Guitard: Service de parasitologie-mycologie, hôpital Saint-Antoine, AP-HP, Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, 75012 Paris, France. Electronic address: juliette.guitard@inserm.fr.
Aspergillus fumigatus is the predominant fungal species causing pulmonary aspergillosis. The present-day anti-aspergillosis arsenal is limited, with a number of molecules occasioning severe side effects (amphotericin B) or provoking significant drug interactions (azole derivatives). Moreover, the recent emergence of azole-resistant A. fumigatus strains is a cause for concern. In this context, antimicrobial peptides (AMPs) are emerging as a promising therapeutic approach and alternative or complement to conventional antifungals.
